Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P08240
UPID:
SRPRA_HUMAN
Alternative names:
Docking protein alpha
Alternative UPACC:
P08240; A6NIB3; B2R5Z8; B4E0H3; E9PJS4; Q9BVJ4
Background:
Signal recognition particle receptor subunit alpha, also known as Docking protein alpha, plays a pivotal role in protein synthesis and cellular function. It is a key component of the signal recognition particle (SRP) complex receptor, ensuring the accurate targeting of nascent secretory proteins to the endoplasmic reticulum (ER) membrane system. This process is facilitated through a GTP-dependent complex formation with SRP54, driving cotranslational protein translocation into the ER.
Therapeutic significance:
Understanding the role of Signal recognition particle receptor subunit alpha could open doors to potential therapeutic strategies.